Literature DB >> 24821788

Tolerance induction in memory CD4 T cells requires two rounds of antigen-specific activation.

Alexandria David1, Frances Crawford1, Paul Garside2, John W Kappler3, Philippa Marrack4, Megan MacLeod5.   

Abstract

A major goal for immunotherapy is to tolerize the immune cells that coordinate tissue damage in autoimmune and alloantigen responses. CD4 T cells play a central role in many of these conditions and improved antigen-specific regulation or removal of these cells could revolutionize current treatments. A confounding factor is that little is known about whether and how tolerance is induced in memory CD4 T cells. We used MHC class II tetramers to track and analyze a population of endogenous antigen-specific memory CD4 T cells exposed to soluble peptide in the absence of adjuvant. We found that such memory T cells proliferated and reentered the memory pool apparently unperturbed by the incomplete activation signals provided by the peptide. Upon further restimulation in vivo, CD4 memory T cells that had been previously exposed to peptide proliferated, provided help to primary responding B cells, and migrated to inflamed sites. However, these reactivated memory cells failed to survive. The reduction in T-cell number was marked by low expression of the antiapoptotic molecule B cell lymphoma 2 (Bcl2) and increased expression of activated caspase molecules. Consequently, these cells failed to sustain a delayed-type hypersensitivity response. Moreover, following two separate exposures to soluble antigen, no T-cell recall response and no helper activity for B cells could be detected. These results suggest that the induction of tolerance in memory CD4 T cells is possible but that deletion and permanent removal of the antigen-specific T cells requires reactivation following exposure to the tolerogenic antigen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821788      PMCID: PMC4040609          DOI: 10.1073/pnas.1406218111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  Protective immunity towards intracellular pathogens.

Authors:  Katharina M Huster; Christian Stemberger; Dirk H Busch
Journal:  Curr Opin Immunol       Date:  2006-06-12       Impact factor: 7.486

2.  Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.

Authors:  Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort
Journal:  Immunology       Date:  2007-04-26       Impact factor: 7.397

Review 3.  Current landscape for T-cell targeting in autoimmunity and transplantation.

Authors:  Daniel R Getts; Sushma Shankar; Emily M L Chastain; Aaron Martin; Meghann Teague Getts; Kathryn Wood; Stephen D Miller
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

Review 4.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

Review 5.  T cell intrinsic roles of autophagy in promoting adaptive immunity.

Authors:  Craig M Walsh; Bryan D Bell
Journal:  Curr Opin Immunol       Date:  2010-04-12       Impact factor: 7.486

Review 6.  Memory T cell subsets, migration patterns, and tissue residence.

Authors:  Scott N Mueller; Thomas Gebhardt; Francis R Carbone; William R Heath
Journal:  Annu Rev Immunol       Date:  2012-12-03       Impact factor: 28.527

7.  Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.

Authors:  Annemarie Hasselberg; Karin Schön; Andrej Tarkowski; Nils Lycke
Journal:  Arthritis Rheum       Date:  2009-06

8.  Memory CD4 T cells that express CXCR5 provide accelerated help to B cells.

Authors:  Megan K L MacLeod; Alexandria David; Amy S McKee; Frances Crawford; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

9.  Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.

Authors:  Melanie D Leech; Chen-Yen Chung; Abigail Culshaw; Stephen M Anderton
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

10.  Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.

Authors:  Soumya Raychaudhuri; Brian P Thomson; Elaine F Remmers; Stephen Eyre; Anne Hinks; Candace Guiducci; Joseph J Catanese; Gang Xie; Eli A Stahl; Robert Chen; Lars Alfredsson; Christopher I Amos; Kristin G Ardlie; Anne Barton; John Bowes; Noel P Burtt; Monica Chang; Jonathan Coblyn; Karen H Costenbader; Lindsey A Criswell; J Bart A Crusius; Jing Cui; Phillip L De Jager; Bo Ding; Paul Emery; Edward Flynn; Pille Harrison; Lynne J Hocking; Tom W J Huizinga; Daniel L Kastner; Xiayi Ke; Fina A S Kurreeman; Annette T Lee; Xiangdong Liu; Yonghong Li; Paul Martin; Ann W Morgan; Leonid Padyukov; David M Reid; Mark Seielstad; Michael F Seldin; Nancy A Shadick; Sophia Steer; Paul P Tak; Wendy Thomson; Annette H M van der Helm-van Mil; Irene E van der Horst-Bruinsma; Michael E Weinblatt; Anthony G Wilson; Gert Jan Wolbink; Paul Wordsworth; David Altshuler; Elizabeth W Karlson; Rene E M Toes; Niek de Vries; Ann B Begovich; Katherine A Siminovitch; Jane Worthington; Lars Klareskog; Peter K Gregersen; Mark J Daly; Robert M Plenge
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

View more
  8 in total

1.  Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.

Authors:  John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

2.  Mechanisms of immunological tolerance in central nervous system inflammatory demyelination.

Authors:  Elisabeth R Mari; Jason N Moore; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Clin Exp Neuroimmunol       Date:  2015-03-22

Review 3.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

Authors:  Niclas E Bengtsson; Jane T Seto; John K Hall; Jeffrey S Chamberlain; Guy L Odom
Journal:  Hum Mol Genet       Date:  2015-10-08       Impact factor: 6.150

Review 4.  The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination.

Authors:  Joshua I Gray; Lotus M Westerhof; Megan K L MacLeod
Journal:  Immunology       Date:  2018-03-23       Impact factor: 7.397

Review 5.  Development and Function of Protective and Pathologic Memory CD4 T Cells.

Authors:  Shafqat Ahrar Jaigirdar; Megan K L MacLeod
Journal:  Front Immunol       Date:  2015-09-08       Impact factor: 7.561

6.  Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.

Authors:  Johannes M van Noort; Malika Bsibsi; Peter J Nacken; Richard Verbeek; Edna H G Venneker
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

7.  Peripheral CD4+ naïve/memory ratio is an independent predictor of survival in non-small cell lung cancer.

Authors:  Peng Yang; Junhong Ma; Xin Yang; Wei Li
Journal:  Oncotarget       Date:  2017-07-18

8.  Tolerance induction in memory CD4 T cells is partial and reversible.

Authors:  Joshua I Gray; Shaima Al-Khabouri; Fraser Morton; Eric T Clambey; Laurent Gapin; Jennifer L Matsuda; John W Kappler; Philippa Marrack; Paul Garside; Thomas D Otto; Megan K L MacLeod
Journal:  Immunology       Date:  2020-10-27       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.